Tozuleristide clinical trials
Also written BLZ-100.
How each study uses tozuleristide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2018 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
Blaze Bioscience Inc. (5) · John Yu (1) · Blaze Bioscience Australia Pty Ltd (1) · University of Washington (1)
Studies
Open first, then newest update. How each study uses tozuleristide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During SurgeryTerminatedPhase 1/2University of WashingtonNCT05316688Written as Tozuleristide
- Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas SystemCompletedPhase 2John YuNCT04743310Written as tozuleristide
- Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing SurgeryCompletedPhase 2/3Blaze Bioscience Inc.NCT03579602Written as tozuleristide
- Study of BLZ-100 in Pediatric Subjects With CNS TumorsCompletedPhase 1Blaze Bioscience Inc.NCT02462629Written as BLZ-100
- Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing SurgeryCompletedPhase 1Blaze Bioscience Inc.NCT02496065Written as BLZ-100
- Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing SurgeryWithdrawnPhase 1Blaze Bioscience Inc.NCT02464332Written as BLZ-100
- Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing SurgeryCompletedPhase 1Blaze Bioscience Inc.NCT02234297Written as BLZ-100
- Safety Study of a Fluorescent Marker to Visualize Cancer CellsCompletedPhase 1Blaze Bioscience Australia Pty LtdNCT02097875Written as BLZ-100
Codes
What other systems call tozuleristide · ClinicalTrials.gg INT000396
- MeSH (NLM) C000604732tozuleristideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 835UH424TUTOZULERISTIDEConfirmed FDA, NLM
- NCI Thesaurus C114979TozuleristideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604732 | tozuleristide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 835UH424TU | TOZULERISTIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C114979 | Tozuleristide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.